title: Tracking growth hormone abuse in sport: performance of marker proteins in a controlled setting.
abstract: Human growth hormone (hGH) abuse in sport is a challenge at present. The current strategy used, known as direct method, is based on the quantification of hGH variants in serum. An alternative strategy, known as indirect method, focuses on serum markers such as insulin-like growth factor I (IGF-I) and procollagen type III N-terminal propeptide (P-III-NP). The indirect method allows a longer window of detection (WOO) of hGH abuse. To evaluate the performance of the indirect method, in parallel to the direct method, a clinical trial with recombinant hGH (rhGH) was conducted on healthy male subjects during 7 days (0.026 mg(-1) kg(-1) person(-1) day(-1)). The data were fit to the discriminant formula proposed in the previously published GH-2000 project. The low sensitivity of the scores, judged from the high number of false negative outcomes, imposed a new discriminant analysis, standarised using local population subjects demographically similar to the ones of the study. The sensitivity of the method significantly increased, highlighting the importance of the standardisation. The indirect method allowed extended window of opportunity (WOO), although two false positive evaluations were observed derived from elevated basal IGF-I and P-III-NP concentrations stressing the need for an independent confirmation method. When direct and indirect methods were combined the best selectivity and sensitivity were achieved.
authors.affiliation: Bio-analysis Group, Neuropsychopharmacology Program, IMIM-Hospital del Mar, Barcelona Biomedical Research Park, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Bosch
authors.forename: G
authors.initials: G
authors.lastname: Such-Sanmartín
authors.forename: J
authors.initials: J
authors.lastname: Segura
authors.forename: R
authors.initials: R
authors.lastname: Gutiérrez-Gallego
mesh_terms: D000328:Adult; D015415:Biomarkers / Q000097:blood; D016002:Discriminant Analysis; D004300:Doping in Sports; D005260:Female; D019382:Human Growth Hormone / Q000008:administration & dosage / Q000097:blood*; D006801:Humans; D007118:Immunoassay; D007334:Insulin-Like Growth Factor I / Q000032:analysis*; D008297:Male; D010446:Peptide Fragments / Q000097:blood*; D058573:Performance-Enhancing Substances / Q000097:blood*; D011347:Procollagen / Q000097:blood*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000097:blood*; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity
chemical_list: D015415:Biomarkers; D010446:Peptide Fragments; D058573:Performance-Enhancing Substances; D011347:Procollagen; D011994:Recombinant Proteins; C041876:procollagen Type III-N-terminal peptide; D019382:Human Growth Hormone; D007334:Insulin-Like Growth Factor I